GlassScriptPhysician profile
Hope Terecia Mitchell
NPI 1134144322
$17,897.61
in general payments reported to CMS, 2019-2025
30 companies · $1,092 in 2025
The $1,092 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $986 · 2020: $487 · 2021: $698 · 2022: $4,146 · 2023: $9,924 · 2024: $564 · 2025: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,536 · Food and Beverage: $2,261 · Travel and Lodging: $517 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,536.00 |
| Food and Beverage | $2,261.34 |
| Travel and Lodging | $516.96 |
| Education | $266.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $5,586.63 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $4,294.96 | 2023-2024 | Sotyktu |
| Janssen Biotech, INC. | $4,067.54 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $1,008.35 | 2019-2025 | |
| Galderma Laboratories, L.P. | $554.25 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $352.66 | 2019-2025 | |
| Pfizer INC. | $310.62 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $286.99 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $186.49 | 2019-2025 | Taltz, Ebglyss |
| Sanofi-Aventis U.S. LLC | $178.99 | 2021-2025 | |
| Regeneron Pharmaceuticals, INC. | $158.69 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $132.01 | 2019-2023 | |
| Leo Pharma INC. | $122.44 | 2021-2025 | Adbry |
| Allergan, INC. | $112.30 | 2019-2022 | |
| Ucb, INC. | $71.18 | 2025 | Bimzelx |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $47.07 | 2020 | |
| Revance Therapeutics, INC. | $46.67 | 2024 | Daxxify |
| Verrica Pharmaceuticals INC. | $42.25 | 2024 | Ycanth |
| Celgene Corporation | $38.83 | 2019 | |
| Incyte Corporation | $38.28 | 2022-2024 | Opzelura |
| Axsome Therapeutics, INC. | $37.96 | 2023-2025 | Auvelity |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.92 | 2019-2020 | |
| Amgen INC. | $37.62 | 2024-2025 | Otezla |
| Eli Lilly and Company | $32.55 | 2025 | |
| Dermira, INC. | $27.94 | 2020-2021 | |
| Prugen, INC. Pharmaceuticals | $19.61 | 2019 | |
| Almirall LLC | $19.53 | 2022 | |
| Fresenius Kabi USA, LLC | $19.28 | 2024 | Idacio |
| Boston Scientific Corporation | $14.15 | 2019 | |
| Epi Health, LLC | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hope Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.